Resveratrol‐Induced Suppression of C‐type Natriuretic Peptide Associates With Increased Vertebral Bone Density in Postmenopausal Women

2023

JBMR Plus, Vol 7, Iss 5, Pp n/a-n/a (2023)

ABSTRACT C‐type natriuretic peptide (CNP) is a paracrine growth factor essential in driving endochondral bone growth in mammals including humans. Despite evidence from animal experiments and tissues that CNP signaling stimulates osteoblast proliferation and osteoclast activity, whether CNP participates in bone remodeling in the mature skeleton is unknown. Using stored plasma samples from a previous randomized controlled clinical trial (RESHAW) of resveratrol supplementation in postmenopausal women exhibiting mild osteopenia, we have studied changes in plasma aminoterminal proCNP (NTproCNP) and concurrent change in bone turnover markers of formation (osteocalcin [OC] and alkaline phosphatase [ALP]) and resorption (C‐terminal telopeptide type 1 collagen [CTX]) with bone mineral density (BMD) over a 2‐year period of study in 125 subjects. In year one, subjects received placebo or resveratrol, switching to resveratrol or placebo, respectively, in year two. Across all time points, there were no significant associations of NTproCNP with CTX, ALP, or OC. During year one, plasma NTproCNP declined significantly in both groups. In the crossover comparison, analysis of change within individuals showed that, compared with placebo, NTproCNP declined after resveratrol (p = 0.011) and ALP increased (p = 0.008), whereas CTX and OC were unchanged. Inverse association of NTproCNP (r = −0.31; p = 0.025) and positive association of OC (r = 0.32, p = 0.022) with BMD at the lumbar spine were identified after resveratrol but not found after placebo. Decline in NTproCNP was independently associated with resveratrol treatment. This is the first evidence that CNP is modulated during a period of increasing BMD in postmenopausal women. Further study of NTproCNP and associations with drivers of bone formation or resorption can be expected to clarify CNP's role during other interventions directed to bone health in adults. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

article

English

Oxford University Press, 2023.

BONE TURNOVER MARKERS, C‐TYPE NATRIURETIC PEPTIDE, OSTEOPOROSIS, RESVERATROL, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935